Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Foundation Medicine, Inc.

http://www.foundationmedicine.com/

Latest From Foundation Medicine, Inc.

COVID-19 Accounts For Most Of 2020’s Pharma Pipeline Growth

The impact of the coronavirus pandemic on the size of the pharma R&D pipeline in 2020 could be felt in a number of ways.

Companies Research & Development

Latest Japan Approvals Include World-First For Pabinafusp

A new batch of marketing authorizations in Japan includes new therapies for high-need cancer indications and rare diseases, and the first nod worldwide for a novel lysosomal disorder treatment that can address serious CNS symptoms.

Japan Approvals

Trio Face 11 Year Wait On Eliquis As US Patents Upheld

Three ANDA sponsors – HEC’s Sunshine Lake, Sigmapharm and Unichem – for generic versions of Eliquis had elected to take their Hatch-Waxman case to trial but were soundly beaten by originator’s Bristol-Myers Squibb and Pfizer. A launch in 2031 could now be their best, and only, option.

Legal Issues Intellectual Property

Novartis's Piqray Gets Europe Green Light At Last

It has taken a while but European regulators have finally followed their US counterparts and approved Piqray, making it the first targeted medicine for HR+/HER2- advanced breast cancer with a PIK3CA mutation.

Approvals Cancer
See All

Company Information

UsernamePublicRestriction

Register